↓ Skip to main content

Children with multiphasic disseminated encephalomyelitis and antibodies to the myelin oligodendrocyte glycoprotein (MOG): Extending the spectrum of MOG antibody positive diseases

Overview of attention for article published in Multiple Sclerosis Journal, July 2016
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (79th percentile)
  • Good Attention Score compared to outputs of the same age and source (73rd percentile)

Mentioned by

policy
1 policy source
twitter
4 X users
wikipedia
2 Wikipedia pages

Citations

dimensions_citation
138 Dimensions

Readers on

mendeley
104 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Children with multiphasic disseminated encephalomyelitis and antibodies to the myelin oligodendrocyte glycoprotein (MOG): Extending the spectrum of MOG antibody positive diseases
Published in
Multiple Sclerosis Journal, July 2016
DOI 10.1177/1352458516631038
Pubmed ID
Authors

Matthias Baumann, Eva-Maria Hennes, Kathrin Schanda, Michael Karenfort, Barbara Kornek, Rainer Seidl, Katharina Diepold, Heinz Lauffer, Iris Marquardt, Jurgis Strautmanis, Steffen Syrbe, Silvia Vieker, Romana Höftberger, Markus Reindl, Kevin Rostásy

Abstract

Myelin oligodendrocyte glycoprotein (MOG) antibodies have been described in children with acute disseminated encephalomyelitis (ADEM), recurrent optic neuritis, neuromyelitis optica spectrum disorders and more recently in children with multiphasic disseminated encephalomyelitis (MDEM). To delineate the clinical, cerebrospinal fluid (CSF) and radiological features of paediatric MDEM with MOG antibodies. Clinical course, serum antibodies, CSF, magnetic resonance imaging (MRI) studies and outcome of paediatric MDEM patients were reviewed. A total of 8 children with two or more episodes of ADEM were identified from a cohort of 295 children with acute demyelinating events. All children had persisting MOG antibodies (median titre: 1:1280). All ADEM episodes included encephalopathy, polyfocal neurological signs and a typical MRI. Apart from ADEM episodes, three children had further clinical attacks without encephalopathy. Median age at initial presentation was 3 years (range: 1-7 years) and median follow-up 4 years (range: 1-8 years). New ADEM episodes were associated with new neurological signs and new MRI lesions. Clinical outcome did range from normal (four of the eight) to mild or moderate impairment (four of the eight). A total of four children received monthly immunoglobulin treatment during the disease course. Children with MDEM and persisting MOG antibodies constitute a distinct entity of relapsing demyelinating events and extend the spectrum of MOG antibody-associated diseases.

X Demographics

X Demographics

The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 104 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Netherlands 1 <1%
Unknown 103 99%

Demographic breakdown

Readers by professional status Count As %
Researcher 16 15%
Student > Postgraduate 12 12%
Student > Doctoral Student 10 10%
Other 10 10%
Student > Bachelor 8 8%
Other 20 19%
Unknown 28 27%
Readers by discipline Count As %
Medicine and Dentistry 41 39%
Neuroscience 18 17%
Biochemistry, Genetics and Molecular Biology 3 3%
Immunology and Microbiology 1 <1%
Economics, Econometrics and Finance 1 <1%
Other 8 8%
Unknown 32 31%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 8. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 July 2019.
All research outputs
#4,233,991
of 24,804,602 outputs
Outputs from Multiple Sclerosis Journal
#1,315
of 3,658 outputs
Outputs of similar age
#71,238
of 362,254 outputs
Outputs of similar age from Multiple Sclerosis Journal
#111
of 422 outputs
Altmetric has tracked 24,804,602 research outputs across all sources so far. Compared to these this one has done well and is in the 82nd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,658 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.1. This one has gotten more attention than average, scoring higher than 63% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 362,254 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 79% of its contemporaries.
We're also able to compare this research output to 422 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 73% of its contemporaries.